Ibrutinib CAS 936563-96-1 | Inhibitor | Supplier
CAS 1642-81-5 | Ibrutinib
| CAS No: | 936563-96-1 |
| Formula: | C25H24N6O2 |
| EINECS: | 805-642-2 |
| Stock Availability: | In stock |
| Brand Name: | Zhishang New Materials |
| Origin: | China |
Product Details of Ibrutinib
Ibrutinib uses
Advantages of Ibrutinib
Related Questions:
Q1: What are the CAS and molecular information representing the ibrutinib you supply? Can they exist consistently in the paper?
A: The product we offer corresponds to CAS 936563-96-1, with a molecular formula of C ₂₅ H ₂₄ N ₆ O two and a molecular weight of 440.50. This info will be consistent in papers such as CoA/labels/packing lists, to avoid the circumstance of “very same material with different names” in inner warehousing systems and regulative papers.
Q2: Is this product a free form or a salt/hydrate type? How can it be shown?
A: Public details exposes that its mainstream supply forms are mainly defined in the form of cost-free bodies, and there are instances of solid-state type monitoring such as crystal/polymorph administration; on the other hand, salt forms, solvates, or other solid-state kinds might also appear in r & d and supply chains. We advise clearly including “type definition + verification approach” in the procurement specifications and applying it in the release examination. We will certainly use NMR, LC-MS, and various other techniques to validate the framework; if it is needed to distinguish between complimentary bodies and salt forms, it is normally required to incorporate counter-ion-related discovery (such as ion chromatography or various other relevant counter-ion quantification/identification techniques); if it is needed to recognize a specific crystal/polymorph, it is generally necessary to make use of XRPD and can be incorporated with solid-state characterization methods such as DSC/TGA to develop a determination requirement.
Q3: Exactly how is stereochemistry managed? Can you supply chiral-related mass information?
A: The systematic naming of ibrutinib consists of (3R) stereochemical details. We generally offer structure confirmation information (such as NMR/LC-MS). If the consumer requires even more stereochemical confirmation, chiral approaches can be added or third-party screening can be contracted out according to job requirements, and the outcomes can be included in the set documents.
Q4: Just how are purity and contaminations defined? Is it sufficient to simply provide a "≥ 99%"?
Q5: Will bad solubility influence our screening or formula? Do you have any type of experience or recommendations?
A: The solubility of ibrutinib in water is relatively low, which is a constant summary in public info; at the same time, its solubility is dramatically related to pH (pKa is about 3.7– 4.0, and there are published information on solubility distinctions at different pH levels). In practice, a more typical technique is to initial prepare a stock remedy making use of natural solvents such as DMSO, and after that dilute it to the target system as needed. If you are conducting approach recognition, it is recommended to consist of “solvent system/dilution sequence/ultrasonic and temperature level control conditions” in the SOP to lower human irregularity.
Q6: What are the advised storage and transportation conditions? Can it be transported at area temperature?
A: There are recommendations for storage space at -20 ° C given in the documentation; in more standardized top quality systems, needs for security monitoring are commonly defined in terms of retesting periods/shelf life. Whether cold chain is required for transportation normally relies on: period, duration of the course, personalizeds clearance uncertainties, and your approach for retesting upon arrival. Our favored strategy is to give packaging and temperature level control options (such as shielded boxes with cooling agent, temperature level recording, and so on) based on the destination climate and transportation period, and plainly specify the suggestions in the documentation.
Q7: What files can you supply? (CoA, SDS, spectra, methods, and so on)
Q8: Can you give a tiny trial example? How can you ensure the uniformity between the sample and the bulk item?
A: Yes, the secret is the “consistency method”: we generally recommend that examples come from the same procedure path and high quality standard as the planned supply, and carry out set retention and crucial indication contrast (such as relevant compound range, web content, moisture/residual solvent window, etc) throughout subsequent scaled-up supply, to minimize the danger of “samples work well yet bulk goods vary”.
